Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands.
Department of Pathology, University Medical Centre Utrecht, Utrecht, The Netherlands
BMJ Open. 2023 Jun 7;13(6):e067437. doi: 10.1136/bmjopen-2022-067437.
Artificial intelligence (AI) has been on the rise in the field of pathology. Despite promising results in retrospective studies, and several CE-IVD certified algorithms on the market, prospective clinical implementation studies of AI have yet to be performed, to the best of our knowledge. In this trial, we will explore the benefits of an AI-assisted pathology workflow, while maintaining diagnostic safety standards.
This is a Standard Protocol Items: Recommendations for Interventional Trials-Artificial Intelligence compliant single-centre, controlled clinical trial, in a fully digital academic pathology laboratory. We will prospectively include prostate cancer patients who undergo prostate needle biopsies (CONFIDENT-P) and breast cancer patients who undergo a sentinel node procedure (CONFIDENT-B) in the University Medical Centre Utrecht. For both the CONFIDENT-B and CONFIDENT-P trials, the specific pathology specimens will be pseudo-randomised to be assessed by a pathologist with or without AI assistance in a pragmatic (bi-)weekly sequential design. In the intervention group, pathologists will assess whole slide images (WSI) of the standard hematoxylin and eosin (H&E)-stained sections assisted by the output of the algorithm. In the control group, pathologists will assess H&E WSI according to the current clinical workflow. If no tumour cells are identified or when the pathologist is in doubt, immunohistochemistry (IHC) staining will be performed. At least 80 patients in the CONFIDENT-P and 180 patients in the CONFIDENT-B trial will need to be enrolled to detect superiority, allocated as 1:1. Primary endpoint for both trials is the number of saved resources of IHC staining procedures for detecting tumour cells, since this will clarify tangible cost savings that will support the business case for AI.
The ethics committee (MREC NedMec) waived the need of official ethical approval, since participants are not subjected to procedures nor are they required to follow rules. Results of both trials (CONFIDENT-B and CONFIDENT-P) will be published in scientific peer-reviewed journals.
人工智能(AI)在病理学领域的应用日益增多。尽管回顾性研究取得了有希望的结果,并且市场上也有几个 CE-IVD 认证的算法,但据我们所知,尚未进行 AI 的前瞻性临床实施研究。在这项试验中,我们将探索 AI 辅助病理工作流程的优势,同时保持诊断安全标准。
这是一项符合标准协议项目:干预性试验人工智能建议的单中心、对照临床试验,在一个完全数字化的学术病理学实验室中进行。我们将前瞻性地纳入在乌得勒支大学医学中心接受前列腺针活检的前列腺癌患者(CONFIDENT-P)和接受前哨淋巴结手术的乳腺癌患者(CONFIDENT-B)。对于 CONFIDENT-B 和 CONFIDENT-P 试验,特定的病理标本将进行伪随机分配,由病理学家在务实的(双)每周顺序设计中进行评估,有无 AI 辅助。在干预组中,病理学家将使用算法的输出协助评估标准苏木精和伊红(H&E)染色切片的全幻灯片图像(WSI)。在对照组中,病理学家将根据当前的临床工作流程评估 H&E WSI。如果未识别到肿瘤细胞或病理学家有疑问,将进行免疫组织化学(IHC)染色。在 CONFIDENT-P 试验中需要招募至少 80 名患者,在 CONFIDENT-B 试验中需要招募 180 名患者,以检测优越性,按 1:1 分配。两项试验的主要终点均为用于检测肿瘤细胞的 IHC 染色程序节省的资源数量,因为这将明确支持 AI 的商业案例的实际成本节约。
伦理委员会(MREC NedMec)豁免了正式伦理批准的需要,因为参与者不受程序约束,也不需要遵守规则。两项试验(CONFIDENT-B 和 CONFIDENT-P)的结果将发表在科学同行评议期刊上。